Anixa Biosciences Inc (ANIX) Stock Price, Quote & News

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 708 9808

Website: www.anixa.com

Address:

3150 Almaden Expressway, Suite 250, San Jose, United States

jshdn Jul. 16 at 1:23 AM

$ANIX https://seekingalpha.com/article/4801449-anixa-biosciences-oncology-platform-with-asymmetric-upside

0 · Reply

delvanbeyond Jul. 15 at 11:53 PM

$ANIX

1 · Reply

rickycv Jul. 15 at 1:24 PM

$ANIX $3.50 Today?

0 · Reply

AZOZ Jul. 15 at 11:54 AM

$BMNR $ANIX $NTWK Insider's love it right!

0 · Reply

redrussian Jul. 15 at 10:55 AM

$NTWK 3.66 $ANIX 3.21

0 · Reply

G101SPM Jul. 14 at 4:16 PM

#INSIDERS $ANIX Chief Executive Officer bought 5,000 shares at $3.15 worth approximately $16K. $SCS Chief Operating Officer sold 12,000 shares at $10.59 - $10.67 worth approximately $128K.

0 · Reply

CEOBuysDisclosures Jul. 14 at 2:45 PM

$ANIX CEO purchased 5,000 shares at $3.15 for a total of $15,750. KUMAR AMIT now owns 574,925 shares. https://ceo-buys.com

0 · Reply

form4ai Jul. 14 at 2:30 PM

$ANIX get alerts like this in real time. Check out www.form4.ai

0 · Reply

10baggerPete Jul. 13 at 6:12 PM

$ANIX does anyone know if these guys actually bought btc with their spare cash or was that just bluster ?

1 · Reply

Kher33 Jul. 11 at 1:47 PM

$ANIX

0 · Reply

Anixa Biosciences: Oncology Platform With Asymmetric Upside

Jul 9, 2025, 8:00 AM EDT - 7 days ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jun 23, 2025, 8:00 AM EDT - 23 days ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 20, 2025, 7:30 AM EDT - 26 days ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 10, 2025, 7:00 AM EDT - 5 weeks ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 9, 2025, 8:00 AM EDT - 5 weeks ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Jun 3, 2025, 7:25 AM EDT - 6 weeks ago

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Jun 2, 2025, 7:00 AM EDT - 6 weeks ago

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

May 19, 2025, 8:00 AM EDT - 2 months ago

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

May 12, 2025, 8:00 AM EDT - 2 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 30, 2025, 8:00 AM EDT - 2 months ago

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Apr 14, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Apr 9, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Apr 1, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Mar 25, 2025, 8:00 AM EDT - 4 months ago

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Mar 24, 2025, 8:00 AM EDT - 4 months ago

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Mar 17, 2025, 8:00 AM EDT - 4 months ago

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Mar 10, 2025, 8:30 AM EDT - 4 months ago

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Mar 3, 2025, 8:00 AM EST - 4 months ago

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Feb 26, 2025, 8:00 AM EST - 5 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Feb 25, 2025, 7:30 AM EST - 5 months ago

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Feb 24, 2025, 8:00 AM EST - 5 months ago

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Feb 18, 2025, 8:00 AM EST - 5 months ago

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Feb 14, 2025, 7:00 AM EST - 5 months ago

Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

Feb 11, 2025, 8:30 AM EST - 5 months ago

Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum

Feb 4, 2025, 8:30 AM EST - 5 months ago

Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention

Jan 21, 2025, 8:30 AM EST - 6 months ago

Anixa Biosciences CEO Provides Letter to Shareholders

Dec 4, 2024, 8:30 AM EST - 8 months ago

Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10

Nov 22, 2024, 8:15 AM EST - 8 months ago

Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 8:20 AM EST - 8 months ago

Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Nov 8, 2024, 1:17 PM EST - 8 months ago

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 6, 2024, 8:30 AM EST - 9 months ago

Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 31, 2024, 8:15 AM EDT - 9 months ago

Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024

Oct 28, 2024, 8:30 AM EDT - 9 months ago

Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 15, 2024, 9:00 AM EDT - 9 months ago

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Oct 7, 2024, 8:30 AM EDT - 10 months ago

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Sep 30, 2024, 8:30 AM EDT - 10 months ago

Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial

Sep 24, 2024, 8:30 AM EDT - 10 months ago

Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine

Sep 18, 2024, 8:30 AM EDT - 10 months ago

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference

Sep 3, 2024, 8:30 AM EDT - 11 months ago

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium

Aug 26, 2024, 8:30 AM EDT - 11 months ago

Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Jul 29, 2024, 8:45 AM EDT - 1 year ago

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting

Jul 23, 2024, 8:15 AM EDT - 1 year ago

Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology

Jul 15, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences Announces $5 Million Share Repurchase Program

Jun 24, 2024, 8:45 AM EDT - 1 year ago

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

May 21, 2024, 7:30 AM EDT - 1 year ago

Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

May 8, 2024, 8:25 AM EDT - 1 year ago

Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines

May 6, 2024, 8:05 AM EDT - 1 year ago

Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja

Apr 30, 2024, 7:45 AM EDT - 1 year ago

Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024

jshdn Jul. 16 at 1:23 AM

$ANIX https://seekingalpha.com/article/4801449-anixa-biosciences-oncology-platform-with-asymmetric-upside

0 · Reply

delvanbeyond Jul. 15 at 11:53 PM

$ANIX

1 · Reply

rickycv Jul. 15 at 1:24 PM

$ANIX $3.50 Today?

0 · Reply

AZOZ Jul. 15 at 11:54 AM

$BMNR $ANIX $NTWK Insider's love it right!

0 · Reply

redrussian Jul. 15 at 10:55 AM

$NTWK 3.66 $ANIX 3.21

0 · Reply

G101SPM Jul. 14 at 4:16 PM

#INSIDERS $ANIX Chief Executive Officer bought 5,000 shares at $3.15 worth approximately $16K. $SCS Chief Operating Officer sold 12,000 shares at $10.59 - $10.67 worth approximately $128K.

0 · Reply

CEOBuysDisclosures Jul. 14 at 2:45 PM

$ANIX CEO purchased 5,000 shares at $3.15 for a total of $15,750. KUMAR AMIT now owns 574,925 shares. https://ceo-buys.com

0 · Reply

form4ai Jul. 14 at 2:30 PM

$ANIX get alerts like this in real time. Check out www.form4.ai

0 · Reply

10baggerPete Jul. 13 at 6:12 PM

$ANIX does anyone know if these guys actually bought btc with their spare cash or was that just bluster ?

1 · Reply

Kher33 Jul. 11 at 1:47 PM

$ANIX

0 · Reply

Kher33 Jul. 10 at 1:16 PM

$ANIX

0 · Reply

PaulLaurent Jul. 9 at 12:13 PM

🕗 8:15am EST PM Update $KZIA – Kazia reported promising early efficacy data from its first-ever triple combination therapy using paxalisib in glioblastoma. Initial signs suggest improved tumor response and tolerability. $OSRH – OSR Holdings unveiled a strategic roadmap for tokenization under Reg A+ and Reg CF frameworks, aiming to integrate blockchain into its real estate and media divisions. $ARTL – Artelo shared positive preclinical efficacy data for ART26.12 in cancer cachexia models, demonstrating appetite stimulation and weight gain potential. $KIDZ – Classover boosted its Solana (SOL) holdings by 295%, surpassing 50,000 SOL, reinforcing its long-term strategy in Web3 education and gaming. $ANIX – Anixa secured a new U.S. patent for its ovarian cancer vaccine tech, expanding its intellectual property around immunotherapy-based prevention.

0 · Reply

OpenOutcrier Jul. 9 at 12:08 PM

$ANIX (+4.5% pre) Breakthrough: New Patent Strengthens Anixa's Ovarian Cancer Vaccine Development with Cleveland Clinic https://ooc.bz/l/69347

0 · Reply

XCat36 Jul. 6 at 2:53 PM

$ANIX Opening a small position and letting it ride the waves for a few years. Solid CEO and the potential to completely chance the lives of millions for the better 🕷️

1 · Reply

SCUBus Jul. 1 at 1:51 AM

$ANIX frankparch, I believe it will work given the initial indications in human patients plus the 100% success rate in the animal lab experiments. As far as timeline, the vaccine has already been proven to be safe (Phase 1). It also has provided evidence of positive reactions in both phase 1a (treatment in diseased patients post mastectomy) and phase 1b (treatment in high-risk patients, pre-disease + pre-preventative mastectomy). Given its very safe profile, once it proves statistically significant at preventing recurrence, I would imagine approval as a vaccine would be faster.

1 · Reply

frankparch Jun. 30 at 1:13 AM

$ANIX SCUBus, this has been helpful. Appreciate it. For the breast cancer, what do you (objectively ?!) think are the odds are that it actually prevents a tumor from growing? Also - for the sake of argument - let's say it does prevent a tumor from growing. Seems quite sad that the preventative vaccine would be so many years out with so many phases for it to be approved for a vaccine, given the severity of breast cancer and how common it is.

1 · Reply

SCUBus Jun. 28 at 2:46 PM

$ANIX I encourage everyone to look at the presentation deck, especially pages 4 and 8: $16 million cash and NO Debt! Historic sale price of other programs: - Kite Pharma to Gilead Sciences for $12 Billion - Juno Therapeutics to Celgene for $9 Billion https://ir.anixa.com/corporate-presentation

0 · Reply

SCUBus Jun. 28 at 2:39 PM

$ANIX Add'l response to frankparch questions: 3) colon/lung/prostate cancers: This is still primary "in the lab" fundamental research using their experience from the breast cancer and ovarian cancer programs. As a result, it will likely be years from now.

0 · Reply

SCUBus Jun. 28 at 2:32 PM

$ANIX Additional response to frankparch questions: 2) Ovarian Treatment: good evidence of attacking the ovarian tumors have been seen beginning with the smallest, sub-therapeutic doses, including basically stopping the progression of the disease. The expectation of the higher doses (therapeutic levels) being tested now are that they may ultimately be curative. The important points are that some women are living more than 1 - 2 years after being told they have only a few months to live. The patients so far are the sickest of the sick, barely hanging on to live, so this appears to be a game changer. It's so promising that the FDA has approved additional doses for patients showing positive results and it was reiterated on the call that this is uncommon for the FDA to do. ... all with NO negative reactions / side effects!

1 · Reply

SCUBus Jun. 28 at 2:24 PM

$ANIX Sharing my response to frankParch as a post: Great slide deck available on the Anixa website. 1) Breast Cancer vaccine: Getting favorable reaction, but can't tell yet about prevention since it takes a number of years for recurrence. Since the women don't have detectable tumors when given the vaccine due to having had a mastectomy, there is nothing to see being attacked. It is designed to be preventative more than a treatment (opposed to the ovarian therapy). Keep in mind that when tested on mice genetically bred to develop breast cancer, 80% of the untreated mice (control group) developed cancer and 0% (NONE!) of the treated mice (test group) developed cancer! And the treated mice could still have healthy babies. The mother mice just couldn't produce breast milk. No negative reactions in human trials other than occasional localized irritation at the injection site.

0 · Reply

frankparch Jun. 27 at 8:13 PM

$ANIX Missed it on the investor call. Did anyone catch? - is the shot that women are getting reducing the tumors/attacking the tumors? Or is it just generating a reaction but we don't quite know if it stops their cancer? - ovarian treatment ... I take it that it is working when a big dose is given, is that right? Any huge side effect? - where are they if anywhere with colon-lung-prostate?

1 · Reply

HooteNanny1776 Jun. 27 at 1:25 PM

$ANIX i believe someone who has recently posted on this board @alphawolftrading is this person. Please do your own DD

0 · Reply

Market Cap	103.08M
Revenue (ttm)	0.00
Net Income (ttm)	-12.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	104,085
Avg Vol	140,528
Day's Range	N/A - N/A
Shares Out	32.21M
Stochastic %K	41%
Beta	0.39
Analysts	Strong Sell
Price Target	$9.00